<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02925091</url>
  </required_header>
  <id_info>
    <org_study_id>MUVienna_Helicobacter</org_study_id>
    <nct_id>NCT02925091</nct_id>
  </id_info>
  <brief_title>Primary Antimicrobial Resistance Patterns of Austrian Helicobacter Pylori Clinical Isolates</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Helicobacter pylori infects ~ 50% of the world's population and a quarter of the European&#xD;
      population. H. pylori is responsible for a large proportion of gastric and duodenal ulcers&#xD;
      and gastritis. Chronic infection with H. pylori is a risk factor for the development of&#xD;
      stomach cancer and MALT (mucosa-associated lymphoid tissue) Lymphoma. The prospects of&#xD;
      success for an antimicrobial eradication therapy is drastically reduced by the significant&#xD;
      increase in antibiotic resistance in Austrian H. pylori isolates. The currently available&#xD;
      data were obtained however from narrowly defined geographical regions and the clinical&#xD;
      routine without information on patient selection. We suspect a considerable geographical&#xD;
      variability of resistance patterns and a clinical bias for a preferential investigation of&#xD;
      patients with unsuccessful, empirical eradication therapy. The objective of the proposed&#xD;
      study is therefore an Austria-wide collection of data on H. pylori resistance in a&#xD;
      prospective clinical study. The data thus collected will enable a significant improvement in&#xD;
      current treatment recommendations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Antimicrobial resistance of H. pylori isolate</measure>
    <time_frame>1 day (Once)</time_frame>
  </primary_outcome>
  <enrollment type="Actual">2000</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Undergoing a diagnostic gastroscopy for the first time in their lives or had a diagnostic&#xD;
        gastroscopy for any reason &gt;10 years ago&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Undergoing a diagnostic gastroscopy for the first time in their lives or had a&#xD;
             diagnostic gastroscopy for any reason &gt;10 years ago&#xD;
&#xD;
          -  Older than 18 years of age&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous H. pylori eradication therapies&#xD;
&#xD;
          -  Antimicrobial treatment for other reasons than H. pylori eradication within 3 months&#xD;
             prior to gastroscopy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>October 4, 2016</study_first_submitted>
  <study_first_submitted_qc>October 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2016</study_first_posted>
  <last_update_submitted>October 4, 2016</last_update_submitted>
  <last_update_submitted_qc>October 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Dr. Christoph Steininger</investigator_full_name>
    <investigator_title>Assoc. Prof.</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

